Literature DB >> 34486397

Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform.

Gene L Bidwell1.   

Abstract

Elastin-like polypeptides (ELPs) are bioengineered proteins that have a unique physical property, a thermally triggered inverse phase transition, that can be exploited for drug delivery. ELP-fusion proteins can be used as soluble biologics, thermally targeted drug carriers, self-assembling nanoparticles, and slow-release drug depots. Because of their unique physical characteristics and versatility for delivery of nearly any type of therapeutic, ELP-based drug delivery systems represent a promising platform for biologics development.

Entities:  

Keywords:  controlled release; depot; drug delivery; elastin-like polypeptide; nanoparticle

Mesh：

Substances：

Year:  2021        PMID： 34486397      PMCID： PMC8560375          DOI： 10.1152/physiol.00026.2021

Source DB:  PubMed          Journal:  Physiology (Bethesda)        ISSN： 1548-9221


  105 in total

1.  The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration.

Authors:  S M Hearst; L R Walker; Q Shao; M Lopez; D Raucher; P J S Vig
Journal:  Neuroscience       Date:  2011-09-17       Impact factor: 3.590

2.  Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.

Authors:  Erika Guise; Jason E Engel; Maxx L Williams; Fakhri Mahdi; Gene L Bidwell; Alejandro R Chade
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

3.  The synthetic polypentapeptide of elastin coacervates and forms filamentous aggregates.

Authors:  D W Urry; M M Long; B A Cox; T Ohnishi; L W Mitchell; M Jacobs
Journal:  Biochim Biophys Acta       Date:  1974-12-18

4.  Design and cellular internalization of genetically engineered polypeptide nanoparticles displaying adenovirus knob domain.

Authors:  Guoyong Sun; Pang-Yu Hsueh; Siti M Janib; Sarah Hamm-Alvarez; J Andrew MacKay
Journal:  J Control Release       Date:  2011-06-14       Impact factor: 9.776

5.  Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy.

Authors:  Maja T Lindenmeyer; Matthias Kretzler; Anissa Boucherot; Silvia Berra; Yoshinari Yasuda; Anna Henger; Felix Eichinger; Stefanie Gaiser; Holger Schmid; Maria P Rastaldi; Robert W Schrier; Detlef Schlöndorff; Clemens D Cohen
Journal:  J Am Soc Nephrol       Date:  2007-05-02       Impact factor: 10.121

Review 6.  Angiogenic cytokines in renovascular disease: do they have potential for therapeutic use?

Authors:  Alejandro R Chade; Nicholas Stewart
Journal:  J Am Soc Hypertens       Date:  2013-02-19

7.  A Maternally Sequestered, Biopolymer-Stabilized Vascular Endothelial Growth Factor (VEGF) Chimera for Treatment of Preeclampsia.

Authors:  Omar C Logue; Fakhri Mahdi; Heather Chapman; Eric M George; Gene L Bidwell
Journal:  J Am Heart Assoc       Date:  2017-12-08       Impact factor: 5.501

8.  A dose-escalating toxicology study of the candidate biologic ELP-VEGF.

Authors:  Jamarius P Waller; Stephen P Burke; Jason Engel; Alejandro R Chade; Gene L Bidwell
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

9.  Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection.

Authors:  J Andrew MacKay; Mingnan Chen; Jonathan R McDaniel; Wenge Liu; Andrew J Simnick; Ashutosh Chilkoti
Journal:  Nat Mater       Date:  2009-11-08       Impact factor: 43.841

Review 10.  Pro-angiogenic therapeutics for preeclampsia.

Authors:  Adrian C Eddy; Gene L Bidwell; Eric M George
Journal:  Biol Sex Differ       Date:  2018-08-25       Impact factor: 5.027
View more
  1 in total

Review 1.  Novel Drug Delivery Technologies and Targets for Renal Disease.

Authors:  Alejandro R Chade; Gene L Bidwell
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.